Ipca Laboratories News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ipca Laboratories Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news and updates on Ipca Laboratories from all sources in a single place.

Ipca Laboratories Ltd.

16 Mar 2026, 11:05AM

1557.00

-0.28%

SAST

Ipca Laboratories Ltd - 524494 - Closure of Trading Window

BSE India

Closure of Trading Window

pdf

Ipca Laboratories Ltd.

06 Mar 2026

1557.00

-0.28%

Ipca Laboratories (IPCA IN) Management Meet Update Steady growth visibility BUY

Buy: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We interacted with the management of IPCA Laboratories (IPCA) to assess its medium-term growth trajectory. The company is prioritizing disciplined execution over aggressive diversification, with a clear focus on strengthening its core businesses while building growth levers. Domestic formulations and branded generics which now contribute 45% of revenues and ~70% of EBITDA, continued to outperform market and grow at healthy levels. We expect IPCA to deliver revenue growth ex Unichem at +11% over FY26-28E with normalization in export generic and API business. This will aid operating...

Ipca Laboratories Ltd. has an average target of 1773.33 from 3 brokers.

Ipca Laboratories Ltd.

18 Feb 2026

1557.00

-0.28%

Broker's Call: Ipca Laboratories (Buy)

Business Line

PL Capital

Ipca Laboratories Ltd. has an average target of 1773.33 from 3 brokers.

Ipca Laboratories Ltd.

17 Feb 2026, 12:00AM

1557.00

-0.28%

Ipca Laboratories (IPCA IN) Q3FY26 Result Update Margin surprise BUY

Buy: Ipca Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Ipca reported strong EBITDA of Rs5.3bn (up 19% YoY) which was 10% above our estimates. Company has witnessed 400bps GMs expansion ex Unichme for 9MFY26 which should sustain given product mix and softer raw material prices. Export API business witnessed recovery in 9MFY26 with 26% YoY growth. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady...

Prabhudas Lilladhar increased Buy price target of Ipca Laboratories Ltd. to 1800.0 on 06 Mar, 2026.

Ipca Laboratories Ltd.

17 Feb 2026, 12:00AM

1557.00

-0.28%

Ipca Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Direct

Revenue break-up Q3FY26 Formulations: 64% (domestic: 41%, export: 22% - export generic: 11%, export institutional: 2%, export branded: 9%), APIs: 13% (export API: 10%, domestic API: 3%), subsidiaries: 23%...

Number of FII/FPI investors decreased from 254 to 248 in Dec 2025 qtr

Ipca Laboratories Ltd.

16 Feb 2026, 05:28PM

1557.00

-0.28%

Ipca Laboratories Results Earnings Call for Q3FY26

Conference Call with Ipca Laboratories Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Ipca Laboratories Ltd.

16 Feb 2026, 11:18AM

1557.00

-0.28%

Company Update

Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copy of Newspaper Publication

pdf

Ipca Laboratories Ltd.

16 Feb 2026, 12:00AM

1557.00

-0.28%

Branded generics drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) reported in-line revenue and better-than-expected EBITDA/PAT (10%/12% beat) in 3QFY26, aided by product mix, favorable currency and a lower tax rate.

Ipca Laboratories Ltd. has an average target of 1773.33 from 3 brokers.

Ipca Laboratories Ltd.

13 Feb 2026

1557.00

-0.28%

to see Rapid results content

Ipca Laboratories Ltd.

13 Feb 2026

1557.00

-0.28%

Result

Ipca Laboratories Ltd - 524494 - Standalone And Consolidated Financial Results For Q3FY26

BSE India

Standalone and Consolidated Financial Results for Q3FY26

pdf

	Dec 2025	Sep 2025	Dec 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	2412.69	2584.36	2265.48	-6.6%	6.5%
Operating Profit Qtr	533.35	544.92	463.08	-2.1%	15.2%
Net Profit Qtr	326.27	282.57	248.14	15.5%	31.5%
Earning Per Share Adjusted latest Qtr	12.86	11.14	9.78	15.4%	31.5%

* Consolidated data

Detailed Results

Is Ipca Laboratories Ltd. worth buying?

372 Votes:

Buy 80.38%

Sell 9.95%

Hold 9.68%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf